On August 22, 2024, Christopher Maggiore, serving as Director and 10% Owner, purchased 31,336 shares of Zivo Bioscience Inc (ZIVO, Financial) as reported in a recent SEC Filing. Following this transaction, the insider now directly holds 498,443 shares of the company.
Zivo Bioscience Inc is engaged in the study, development, and commercialization of natural bioactive compounds derived from its proprietary algal cultures to address dietary and health-related markets.
The transaction occurred when shares of Zivo Bioscience Inc were priced at $8.34, resulting in a total investment by the insider of approximately $261,043.44. The company's market cap following the purchase is $27.771 million.
Over the past year, Christopher Maggiore has been an active buyer in the stock, purchasing a total of 239,872 shares. There have been no sales recorded by the insider during this period. The overall insider transaction history for Zivo Bioscience Inc shows a trend of more purchases than sales, with 6 insider buys and 0 insider sells over the last year.
For investors, understanding the behavior of company insiders can provide valuable insights, as their buying and selling decisions can reflect their view on the company's future prospects. The recent purchase by Christopher Maggiore might indicate a positive outlook on the company's valuation and future performance.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
